Caroline Smith‐Burchnell

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations · Full text

Standard Deviations, Immunology, Pharmacotherapy +19

Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry

Mike Westby, Caroline Smith‐Burchnell, Julie Mori et al. · Journal of Virology · 2006 · 346 citations

Phenotypic Susceptibility Assays, Immunology, Ccr5 Antagonist +16

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1

Romuald Corbau, Julie Mori, Chris Phillips et al. · Antimicrobial Agents and Chemotherapy · 2010 · 63 citations · Full text

Immunology, Molecular Biology, Pharmacotherapy +16

HIV-1 proteinase is required for synthesis of pro-viral DNA

C. Baboonian, Angus Dalgleish, Lynne Bountiff et al. · Biochemical and Biophysical Research Communications · 1991 · 48 citations

Viral Replication, Natural Sciences, Human Retrovirus +6

A search for retrovirus infection in systemic lupus erythematosus and rheumatoid arthritis.

B K Pelton, Margaret North, R G Palmer et al. · Annals of the Rheumatic Diseases · 1988 · 35 citations · Full text